Neurodegenerative disorders are being fought with €28m
Danish Teitur Trophics ApS announced the completion of a €28m Series A funding to progress drugs against several neurodegenerative diseases.
european-biotechnology.comI can help with the latest on Tentyris. Here’s a concise update based on recent racing coverage:
-
Tentyris, the Godolphin three-year-old sprinter, has been heavily featured in Australian racing chatter around spring campaigns, with expectations focused on high-grade sprint targets in Australia and potential international plans for 2027. This includes discussions of a likely route through major autumn and spring sprints in Australia and possible travel later in the year.
-
Recent speed analyses from Flemington race days highlighted Tentyris as one of the fastest performers on the card, reinforcing his status as a top-tier sprinter in current form. These assessments often frame him as a leading contemporary in Age 3 sprinting.
-
There has been industry commentary about Tentyris’s longer-term plans, including potential stud considerations after peak racing campaigns, though no definitive retirement date has been confirmed in the latest reports.
If you’d like, I can pull a quick two-way summary table of Tentyris’s confirmed race appearances and results from the latest season, or set up a short digest of upcoming targets and potential travel plans based on the most recent industry reports.